Literature DB >> 21149595

Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies.

Kate L Seib1, Brunella Brunelli, Barbara Brogioni, Emmanuelle Palumbo, Stefania Bambini, Alessandro Muzzi, Federica DiMarcello, Sara Marchi, Arie van der Ende, Beatrice Aricó, Silvana Savino, Maria Scarselli, Maurizio Comanducci, Rino Rappuoli, Marzia M Giuliani, Mariagrazia Pizza.   

Abstract

Neisseria meningitidis is a commensal of the human nasopharynx but is also a major cause of septicemia and meningitis. The meningococcal factor H binding protein (fHbp) binds human factor H (fH), enabling downregulation of complement activation on the bacterial surface. fHbp is a component of two serogroup B meningococcal vaccines currently in clinical development. Here we characterize 12 fHbp subvariants for their level of surface exposure and ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Flow cytometry and Western analysis revealed that all strains examined expressed fHbp on their surface to different extents and bound fH in an fHbp-dependent manner. However, differences in fH binding did not always correlate with the level of fHbp expression, indicating that this is not the only factor affecting the amount of fH bound. To overcome the issue of strain variability in fHbp expression, the MC58ΔfHbp strain was genetically engineered to express different subvariants from a constitutive heterologous promoter. These recombinant strains were characterized for fH binding, and the data confirmed that each subvariant binds different levels of fH. Surface plasmon resonance revealed differences in the stability of the fHbp-fH complexes that ranged over 2 orders of magnitude, indicating that differences in residues between and within variant groups can influence fH binding. Interestingly, the level of survival in human sera of recombinant MC58 strains expressing diverse subvariants did not correlate with the level of fH binding, suggesting that the interaction of fHbp with fH is not the only function of fHbp that influences serum resistance. Furthermore, cross-reactive bactericidal activity was seen within each variant group, although the degree of activity varied, suggesting that amino acid differences within each variant group influence the bactericidal antibody response.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21149595      PMCID: PMC3028832          DOI: 10.1128/IAI.00891-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood.

Authors:  Kathleen Y Dunphy; Peter T Beernink; Barbara Brogioni; Dan M Granoff
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

2.  Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus.

Authors:  Marzia M Giuliani; Alessia Biolchi; Davide Serruto; Francesca Ferlicca; Kay Vienken; Philipp Oster; Rino Rappuoli; Mariagrazia Pizza; John Donnelly
Journal:  Vaccine       Date:  2010-05-21       Impact factor: 3.641

Review 3.  Research and development of universal influenza vaccines.

Authors:  Lanying Du; Yusen Zhou; Shibo Jiang
Journal:  Microbes Infect       Date:  2010-01-15       Impact factor: 2.700

4.  Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis.

Authors:  Ellen Murphy; Lubomira Andrew; Kwok-Leung Lee; Deborah A Dilts; Lorna Nunez; Pamela S Fink; Karita Ambrose; Ray Borrow; Jamie Findlow; Muhamed-Kheir Taha; Ala-Eddine Deghmane; Paula Kriz; Martin Musilek; Jitka Kalmusova; Dominique A Caugant; Torill Alvestad; Leonard W Mayer; Claudio T Sacchi; Xin Wang; Diana Martin; Anne von Gottberg; Mignon du Plessis; Keith P Klugman; Annaliesa S Anderson; Kathrin U Jansen; Gary W Zlotnick; Susan K Hoiseth
Journal:  J Infect Dis       Date:  2009-08-01       Impact factor: 5.226

5.  Complement regulator factor H as a serum biomarker of multiple sclerosis disease state.

Authors:  Gillian Ingram; Svetlana Hakobyan; Claire L Hirst; Claire L Harris; Trevor P Pickersgill; Mark D Cossburn; Sam Loveless; Neil P Robertson; Bryan Paul Morgan
Journal:  Brain       Date:  2010-04-25       Impact factor: 13.501

6.  Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.

Authors:  Han-Qing Jiang; Susan K Hoiseth; Shannon L Harris; Lisa K McNeil; Duzhang Zhu; Cuiwen Tan; Adrienne A Scott; Kristin Alexander; Kathryn Mason; Lynn Miller; Ida DaSilva; Michelle Mack; Xiao-Juan Zhao; Michael W Pride; Lubomira Andrew; Ellen Murphy; Michael Hagen; Roger French; Ashoni Arora; Thomas R Jones; Kathrin U Jansen; Gary W Zlotnick; Annaliesa S Anderson
Journal:  Vaccine       Date:  2010-07-07       Impact factor: 3.641

7.  Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.

Authors:  Jay Lucidarme; Maurizio Comanducci; Jamie Findlow; Stephen J Gray; Edward B Kaczmarski; Malcolm Guiver; Pamela J Vallely; Philipp Oster; Mariagrazia Pizza; Stefania Bambini; Alessandro Muzzi; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2010-04-07

8.  The modular architecture of meningococcal factor H-binding protein.

Authors:  Peter T Beernink; Dan M Granoff
Journal:  Microbiology (Reading)       Date:  2009-07-02       Impact factor: 2.777

9.  The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement.

Authors:  Lisa A Lewis; Jutamas Ngampasutadol; Ruth Wallace; Jane E A Reid; Ulrich Vogel; Sanjay Ram
Journal:  PLoS Pathog       Date:  2010-07-29       Impact factor: 6.823

10.  Variation of the factor H-binding protein of Neisseria meningitidis.

Authors:  Carina Brehony; Daniel J Wilson; Martin C J Maiden
Journal:  Microbiology (Reading)       Date:  2009-09-03       Impact factor: 2.777

View more
  37 in total

1.  The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci.

Authors:  Lisa A Lewis; Matthew Carter; Sanjay Ram
Journal:  J Immunol       Date:  2012-04-13       Impact factor: 5.422

2.  Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined.

Authors:  Massimiliano Biagini; Marco Spinsanti; Gabriella De Angelis; Sara Tomei; Ilaria Ferlenghi; Maria Scarselli; Fabio Rigat; Nicola Messuti; Alessia Biolchi; Alessandro Muzzi; Giulia Anderloni; Brunella Brunelli; Elena Cartocci; Francesca Buricchi; Chiara Tani; Maria Stella; Monica Moschioni; Elena Del Tordello; Annalisa Colaprico; Silvana Savino; Marzia M Giuliani; Isabel Delany; Mariagrazia Pizza; Paolo Costantino; Nathalie Norais; Rino Rappuoli; Vega Masignani
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-17       Impact factor: 11.205

3.  Genetic characteristics of Neisseria meningitidis serogroup B strains carried by adolescents living in Milan, Italy: implications for vaccine efficacy.

Authors:  Susanna Esposito; Alberto Zampiero; Leonardo Terranova; Valentina Montinaro; Alessia Scala; Valentina Ansuini; Nicola Principi
Journal:  Hum Vaccin Immunother       Date:  2013-07-23       Impact factor: 3.452

4.  Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen.

Authors:  Enrico Malito; Agnese Faleri; Paola Lo Surdo; Daniele Veggi; Giulietta Maruggi; Eva Grassi; Elena Cartocci; Isabella Bertoldi; Alessia Genovese; Laura Santini; Giacomo Romagnoli; Erica Borgogni; Sébastien Brier; Carla Lo Passo; Maria Domina; Flora Castellino; Franco Felici; Stijn van der Veen; Steven Johnson; Susan M Lea; Christoph M Tang; Mariagrazia Pizza; Silvana Savino; Nathalie Norais; Rino Rappuoli; Matthew J Bottomley; Vega Masignani
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-08       Impact factor: 11.205

5.  Vaccines, reverse vaccinology, and bacterial pathogenesis.

Authors:  Isabel Delany; Rino Rappuoli; Kate L Seib
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

6.  The Dual Role of Lipids of the Lipoproteins in Trumenba, a Self-Adjuvanting Vaccine Against Meningococcal Meningitis B Disease.

Authors:  Yin Luo; Olga V Friese; Herbert A Runnels; Lakshmi Khandke; Gary Zlotnick; Ann Aulabaugh; Thomas Gore; Eugene Vidunas; Stephen W Raso; Elena Novikova; Emilia Byrne; Michael Schlittler; Donald Stano; Robert L Dufield; Sandeep Kumar; Annaliesa S Anderson; Kathrin U Jansen; Jason C Rouse
Journal:  AAPS J       Date:  2016-09-07       Impact factor: 4.009

7.  The effect of iron availability on transcription of the Neisseria meningitidis fHbp gene varies among clonal complexes.

Authors:  Holly Sanders; Carina Brehony; Martin C J Maiden; Caroline Vipond; Ian M Feavers
Journal:  Microbiology (Reading)       Date:  2012-01-12       Impact factor: 2.777

8.  Neisseria meningitidis Urethritis Outbreak Isolates Express a Novel Factor H Binding Protein Variant That Is a Potential Target of Group B-Directed Meningococcal (MenB) Vaccines.

Authors:  Yih-Ling Tzeng; Serena Giuntini; Zachary Berman; Soma Sannigrahi; Dan M Granoff; David S Stephens
Journal:  Infect Immun       Date:  2020-11-16       Impact factor: 3.441

9.  An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands.

Authors:  Stefania Bambini; Jurgen Piet; Alessandro Muzzi; Wendy Keijzers; Sara Comandi; Lisa De Tora; Mariagrazia Pizza; Rino Rappuoli; Diederik van de Beek; Arie van der Ende; Maurizio Comanducci
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

10.  Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines.

Authors:  Monica Konar; Dan M Granoff; Peter T Beernink
Journal:  J Infect Dis       Date:  2013-05-28       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.